Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Payables: 2020-2025

Historic Payables for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to $2.6 million.

  • Lyell Immunopharma's Payables fell 28.59% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year decrease of 14.09%. This contributed to the annual value of $5.4 million for FY2024, which is 11.40% up from last year.
  • As of Q3 2025, Lyell Immunopharma's Payables stood at $2.6 million, which was down 24.00% from $3.4 million recorded in Q2 2025.
  • Lyell Immunopharma's 5-year Payables high stood at $6.5 million for Q1 2022, and its period low was $2.6 million during Q3 2025.
  • Over the past 3 years, Lyell Immunopharma's median Payables value was $4.4 million (recorded in 2023), while the average stood at $4.4 million.
  • Per our database at Business Quant, Lyell Immunopharma's Payables tumbled by 65.87% in 2021 and then surged by 36.68% in 2023.
  • Lyell Immunopharma's Payables (Quarterly) stood at $3.2 million in 2021, then rose by 22.14% to $3.9 million in 2022, then climbed by 22.98% to $4.8 million in 2023, then rose by 11.40% to $5.4 million in 2024, then decreased by 28.59% to $2.6 million in 2025.
  • Its Payables was $2.6 million in Q3 2025, compared to $3.4 million in Q2 2025 and $3.7 million in Q1 2025.